Arkin Holdings launches $140m healthcare fund
Israel’s Arkin Holdings has raised $140m of commitments for its latest investment vehicle focused on pharmaceutical and biotechnology companies.
Arkin Bio-Ventures II received commitments from institutional investors such as Migdal and Phoenix Group.
The firm will use Fund II to invest in 10 to 12 companies developing therapies such as gene therapy, and RNA/DNA-based therapy.
“Arkin Bio-Ventures II builds on the success of our earlier, well-established and lucrative fund. Together with our partners, we look forward to further successful investments in novel and world class technologies and organizations,” said Mori Arkin, founder and chairman of Arkin Holdings.
“We are excited to collaborate with Migdal and Phoenix Group, two of Israel’s largest and most sophisticated institutional investors.”
Since launch, Arkin has backed more than 10 private companies including, cCAM Biotherapeutics, Keros Therapeutics, Censa Pharmaceuticals and Oncorus.
Copyright © 2020 AltAssets